Phase 1, Open-label, Safety And Feasibility Study Of Implantation Of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (Rpe) Living Tissue Equivalent) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2017
At a glance
- Drugs PF 5206388 (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 19 Dec 2017 Planned End Date changed from 1 Mar 2017 to 20 Nov 2018.
- 19 Dec 2017 Planned primary completion date changed from 1 Mar 2017 to 20 Nov 2018.
- 04 Jan 2017 Status changed from active, no longer recruiting to suspended.